Therapeutic Asset Ratings

8,400 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Entinostat Refractory Pancreatic Carcinoma	National Cancer Institute (NCI)	P1/2	CCC (53)
ETOPOSIDE Lymphoplasmacytic Lymphoma	City of Hope Medical Center	P1/2	CCC (53)
Fludarabine Brain Neoplasm	Essen Biotech	P1/2	CCC (53)
Fludarabine Classic Hodgkin Lymphoma	New York Medical College	P1/2	CCC (53)
Fludarabine Nonpapillary Renal Cell Carcinoma	M.D. Anderson Cancer Center	P1/2	CCC (53)
Fludarabine Digestive System Cancer	National Cancer Institute (NCI)	P1/2	CCC (53)
Fludarabine Head And Neck Cancer	Zelluna Immunotherapy AS	P1/2	CCC (53)
Fludarabine Malignant Glioma	Beijing Biotech	P1/2	CCC (53)
Fludarabine Pancreatic Adenocarcinoma	University of Pennsylvania	P1/2	CCC (53)
Fludarabine Sezary Syndrome	UNC Lineberger Comprehensive Cancer Center	P1/2	CCC (53)
Fludarabine Urothelial Carcinoma	Beijing Biotech	P1/2	CCC (53)
FLUDEOXYGLUCOSE Brain Neoplasm	Peking Union Medical College Hospital	P1/2	CCC (53)
FLUDEOXYGLUCOSE Cancer	Jonsson Comprehensive Cancer Center	P1/2	CCC (53)
FLUOROURACILUM Cutaneous Melanoma	Immuneering Corporation	P1/2	CCC (53)
FLUOROURACILUM KRAS Mutation-Related Tumors	Institut de Recherches Internationales Servier	P1/2	CCC (53)
FLUOROURACILUM Small Cell Lung Carcinoma	Seagen, a wholly owned subsidiary of Pfizer	P1/2	CCC (53)
gpc3-car-t cells Hepatocellular Carcinoma	RenJi Hospital	P1/2	CCC (53)
h3b-6545 Breast Neoplasm	Eisai Co., Ltd.	P1/2	CCC (53)
IMMUNOGLOBULIN G2, ANTI-(HUMAN CTLA-4 (ANTIGEN)) (HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 HEAVY CHAIN) DISULPHIDE WITH HUMAN MONOCLONAL CP-675206 CLONE 11.2.1 LIGHT CHAIN, DIMER Peritoneal Neoplasm	AstraZeneca	P1/2	CCC (53)
Inno-206 Cutaneous Melanoma	GI Innovation, Inc.	P1/2	CCC (53)
Inno-206 Peritoneal Carcinomatosis	National Cancer Institute (NCI)	P1/2	CCC (53)
Ino-9012 Hepatocellular Carcinoma	Geneos Therapeutics	P1/2	CCC (53)
Ipilimumab B-Cell Chronic Lymphocytic Leukemia	M.D. Anderson Cancer Center	P1/2	CCC (53)
Ipilimumab Recurrent Malignant Solid Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (53)
Irinotecan KRAS Mutation-Related Tumors	Institut de Recherches Internationales Servier	P1/2	CCC (53)

Showing 426 to 450 of 8,400 assets

PreviousPage 18 of 336Next